New Sartorius QbD tool supports faster Raman model building
ambr 15 cell culture system with ambr analysis module showing BioPAT Spectro port, to which a probe for Raman spectrometer is connected.
Unlocking the potential of Raman spectroscopy as a high throughput analytical technique for monitoring cell culture in mini bioreactors.
Sartorius has introduced BioPAT Spectro, a Quality by Design (QbD) tool for use with its ambr automated micro and mini bioreactor systems and with the single-use production bioreactors BIOSTAT STR. The new tool offers access to Raman spectroscopy analysis in high throughput process development, supporting faster Raman model building and accelerating scale-up into commercial manufacturing.
Raman spectroscopy is non-invasive and can measure multiple analytes, making it suitable as a Process Analytical Technologies (PAT) method for process control and monitoring of cell cultures. Off-line approaches to obtain and consolidate enough data to produce a robust Raman model can be time‐consuming and costly. The new BioPAT Spectro Tool, can be retrofitted into ambr 15 cell culture and ambr 250 high throughput systems, and enables quick and simple sampling for integrated at-line analysis of a large number of analytes by Raman spectroscopy in a Design of Experiments (DoE) approach.
Consisting of a multi-use flow cell integrated into the ambr analysis module, BioPAT Spectro in ambr has been successfully demonstrated by major pharmaceutical companies and is compatible with Raman spectrometers from Kaiser Optical Systems and Tornado Spectral Systems. The online Raman spectroscopy data alongside data from the ambr process and selected integrated analysers, is automatically collated by the ambr software and can be easily transferred to SIMCA Multivariate Data Analysis (MVDA) software to build robust Raman models.
One benefit of using BioPAT Spectro with ambr system is that all integrated sampling, sample analysis, data collection, and consolidation is automated, making walk-away Raman spectroscopy analysis in high throughput process development a reality. In addition, one ambr run in 24 mini bioreactors can cover a wide design space, rapidly providing all the data required to build robust Raman models to support QbD, in less than half the time of the conventional benchtop approach.
Developed with scalability in mind, BioPAT Spectro’s flow cell’s Raman probe interface and optical path design is identical across scales so it enables time-saving, automated in-line Raman spectroscopy with Sartorius’ BIOSTAT STR single-use bioreactors. The integrated qualified and ready-to-use single-use spectroscopy port in Flexsafe STR bags for BIOSTAT STR bioreactors will be launched in the near future.
"Unlocking the potential of Raman spectroscopy as a high throughput analytical technique for monitoring cell culture in mini bioreactors has been a key goal of process development scientists for a number of years,” commented Dr Svea Cheeseman, Product Manager Process Analytical Technology at Sartorius. “We are showcasing the BioPAT Spectro at IFPAC and BPI West this year and look forward to discussing with scientists how they can use this new analytical technique with ambr systems to build and utilize robust Raman models, in a workflow which will support their QbD programs, while minimizing resource costs and biologics’ manufacturing timelines,” adds Dr Cheeseman.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...